{"id":"W4379281896","doi":"10.1200/jco.2023.41.16_suppl.5013","title":"Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Placebo; Prostate cancer; Internal medicine; Quality of life (healthcare); Cancer; Oncology; Alternative medicine; Androgen receptor; Nursing; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003206888,0.0004569943,0.0008406607,0.0004234627,0.0002346004,0.0005333674,0.0003521896,0.0006689232,0.002258155],"category_scores_gemma":[0.002857317,0.0002207616,0.001929875,0.0005179252,0.0003518216,0.000599511,0.0004332565,0.001115635,0.0002160845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004045698,"about_ca_system_score_gemma":0.0003390476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007347654,"about_ca_topic_score_gemma":0.001075208,"domain_scores_codex":[0.9985766,0.0008218098,0.0001063677,0.0001863957,0.0001942072,0.0001146327],"domain_scores_gemma":[0.9975687,0.0007955263,0.001115971,0.00008655345,0.00009494159,0.0003383851],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5378555,0.005600764,0.3471088,0.001740271,0.01181492,0.0001503919,0.0003513364,0.003624439,0.003070068,0.0002243415,0.002349503,0.08610967],"study_design_scores_gemma":[0.03458903,0.1522118,0.7998644,0.0001531476,0.005870478,0.0002398178,0.000200269,0.003397588,0.001311875,0.0003179226,0.001775151,0.00006854323],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948205,0.002546538,0.0001808194,0.0001140749,0.00002947076,0.0001211358,0.00151839,0.00001549135,0.0006535699],"genre_scores_gemma":[0.997798,0.0003836117,0.0001398417,0.0001120442,0.00003415535,0.0001687189,0.001030154,0.000002706211,0.0003309293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003206888,"threshold_uncertainty_score":0.01695991,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1930233131307427,"score_gpt":0.5105133045419311,"score_spread":0.3174899914111884,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}